The Association Between COVID-19 Vaccination and Confirmed Patients with Hospitalization in Omicron Era: A Retrospective Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Jan 11

PMID 38206726

Authors

Ming-Hung Chang

Kuang-Ming Liao

Affiliations

Soon will be listed here.

Abstract

With the emergence of Omicron variant of severe acute respiratory syndrome coronavirus 2, Taiwan has encountered the greatest coronavirus disease 2019 (COVID-19) pandemic since 2022 spring. We analyzed the characteristics, vaccinations, and outcomes of hospitalized COVID-19 patients quarantined in a dedicated ward. This retrospective study enrolled hospitalized COVID-19 patients in the dedicated wards of a district hospital in southern Taiwan from May 2022 to July 2022. We assessed in-hospital mortality, hospital length of stay (LOS), and dedicated ward LOS. Among 209 COVID-19 patients, the in-hospital mortality rates were 20.7% and 29.7% (P = .145) in patients with and without vaccination. A shorter dedicated ward LOS was noted in the vaccination group, with marginal statistical significance. Age, Charlson Comorbidity Index, and quick Sequential Organ Failure Assessment score were recognized as strong prognostic indicators for mortality in multivariable analysis. Vaccination demonstrated significant lower odds of death among relatively young populations in subgroup analysis. COVID-19 vaccination had significant efficacy in hospitalized COVID-19 patients in the relatively young group, and the effect may decline among individuals with advanced age and multiple comorbidities.

Citing Articles

Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron Variants.

Cheng H, Chang K, Wu B, Teo M, Hung W, Wu H Infect Drug Resist. 2025; 18():151-160.

PMID: 39803308 PMC: 11725234. DOI: 10.2147/IDR.S479896.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Shao W, Zhang W, Fang X, Yu D, Wang X . Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. J Microbiol Immunol Infect. 2022; 55(3):387-394. PMC: 9040366. DOI: 10.1016/j.jmii.2022.03.007. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D . COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. JMIR Public Health Surveill. 2021; 8(1):e29872. PMC: 8734610. DOI: 10.2196/29872. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

Mohammed I, Nauman A, Paul P, Ganesan S, Chen K, Jalil S . The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022; 18(1):2027160. PMC: 8862168. DOI: 10.1080/21645515.2022.2027160. View

Abu-Raddad L, Chemaitelly H, Ayoub H, Almukdad S, Yassine H, Al-Khatib H . Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022; 386(19):1804-1816. PMC: 8929389. DOI: 10.1056/NEJMoa2200797. View

10.

Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q . The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2021; 11(1):1-5. PMC: 8725892. DOI: 10.1080/22221751.2021.2017757. View

11.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

12.

Chalkias S, Harper C, Vrbicky K, Walsh S, Essink B, Brosz A . A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022; 387(14):1279-1291. PMC: 9511634. DOI: 10.1056/NEJMoa2208343. View

13.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

14.

Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C . Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022; 400(10360):1305-1320. PMC: 9560746. DOI: 10.1016/S0140-6736(22)01656-7. View

15.

Willett B, Grove J, MacLean O, Wilkie C, De Lorenzo G, Furnon W . Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022; 7(10):1709. PMC: 9483304. DOI: 10.1038/s41564-022-01241-6. View

16.

Kuswardhani R, Henrina J, Pranata R, Lim M, Lawrensia S, Suastika K . Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020; 14(6):2103-2109. PMC: 7598371. DOI: 10.1016/j.dsx.2020.10.022. View

17.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

18.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

19.

Tenforde M, Self W, Adams K, Gaglani M, Ginde A, McNeal T . Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021; 326(20):2043-2054. PMC: 8569602. DOI: 10.1001/jama.2021.19499. View

20.

Butt A, Talisa V, Shaikh O, Omer S, Mayr F . Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. Clin Infect Dis. 2022; 75(12):2161-2168. PMC: 11487159. DOI: 10.1093/cid/ciac328. View